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Immunization of mice with Borrelia burgdorferi lp54 gene 
encoded recombinant proteins does not provide protection 
against tick transmitted infectious challenge
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Abstract
The Borrelia burgdorferi outer surface membrane proteins BBA65, BBA66, BBA69, BBA70, and 
BBA73 were tested for their ability to confer protection against B. burgdorferi infection challenge. 
Mice were immunized with recombinant forms of the proteins singly or in combinations. 
Following initial protein inoculation and booster injections, seroconversion was confirmed prior to 
B. burgdorferi challenge by tick bite. Despite mice having high antibody titers for each antigen, no 
significant protections against the challenge infections were observed. These results demonstrate 
that these recombinant proteins were not protective and reflects the challenges confronted to 
identify effective novel vaccine candidates for Lyme disease.
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1. Introduction
Lyme disease, or Lyme borreliosis, caused by the bacterium Borrelia burgdorferi (sensu lato 
family) via transmission by tick bites, remains a major public health concern in North 
America and temperate regions worldwide. In the United States, cases continue to rise 
despite integrated prevention efforts including personal protective measures, acaricide 
application, and control of tick populations through management of small mammalian 
reservoir and deer hosts [1,2]. Although each control and prevention application has merit 
and can be effective, they have specific limitations. It has been proposed that vaccination 
would be a more effective strategy to reduce the Lyme disease case burden [3].
A commercially available vaccine was manufactured and sold until 2002 when it was 
withdrawn for multiple reasons [4] and there is currently no human vaccine for Lyme 
disease. The commercial vaccine (Lymerix) was composed of the B. burgdorferi protein 
antigen termed OspA (outer surface protein A). OspA is present on B. burgdorferi that reside 
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in unfed nymphal and adult stage ticks. When the tick engorges on blood from an OspA-
vaccinated individual, the OspA-specific antibodies present in the blood eradicate the 
organisms within the tick, thereby preventing transmission to the human host [5]. 
Interestingly, when B. burgdorferi infects a non-vaccinated host following a tick bite, the 
OspA antigen is not produced by the organism. Therefore, protection by this vaccine can 
only occur if the individual has been prophylactically immunized and has sufficient titer of 
circulating anti-OspA antibodies in the blood at the time of infected tick bite.
Second generation vaccine candidates have focused on B. burgdorferi antigens that are 
synthesized within the tick and/or upon establishment of infection in the host. Several 
candidate proteins have been identified that fit this criteria and have been evaluated for 
protective capability following immunization in experimental animals [6]. Most have shown 
little or no immunizing protection against tick bite challenge with the exception of OspC 
which has shown the best potential as a protective immunogen [7–10]. However, doubts 
have arisen that with OspC strain heterogeneity, cross protection from different B. 
burgdorferi strains would be limited. Other strategies for Lyme disease vaccine candidates 
have been proposed including tick protein antigens (anti-tick vaccine), alternate novel B. 
burgdorferi proteins, and a combination of both [6,11].
The B. burgdorferi genome consists of an approximate 900 kilobase chromosome and 
numerous linear and circular plasmids [12]. Although some plasmids are dispensible for B. 
burgdorferi viability, the 54 kilobase linear plasmid (lp54) is regularly maintained, an 
indication that genes on this plasmid encode proteins with essential functions. A contiguous 
series of lp54 genes with annotated designations of BBA64, −65, −66, −69, −70, and −73, 
have been extensively studied, and they have been referred to as a paralogous gene family 
[12]. Several of these genes have been predicted by microarray studies to be highly 
upregulated under conditions of tick blood feeding, mammalian infection, and other 
environmental conditions such as pH and temperature [13–15]. The outer surface location of 
the lipoproteins encoded by these genes, their elicitation of host antibody responses during 
infection, and that antibodies against them are bactericidal, have led to proposals that these 
proteins are candidates as vaccinogens [16–18]. In this study, we evaluated the protective 
efficacy afforded by recombinant forms of these proteins via mouse immunizations, either 
singly or in combinations, followed by infectious tick transmitted B. burgdorferi challenge.
2. Materials and methods
2.1. Bacterial strains, ticks, and mice
B. burgdorferi clonal infectious strain B31-A3 was used in all mouse/tick challenge 
experiments, following cultivation in BSK-II complete media in sealed tubes at 34 °C in a 
5% CO2 incubator.
Generation of infected I. scapularis tick colonies and assessment of infection with B. 
burgdorferi were performed as described [18].
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2.2. Preparation of recombinant proteins
The bba64, −65, −66, −69, −70, −73, and ospC coding sequences minus the signal peptide 
were cloned for recombinant protein expression using the Expresso T7 Cloning and 
Expression System (Lucigen Corporation, Middleton, WI). The genes were amplified from 
B. burgdorferi B31 genomic DNA with primers designed to ligate into the linearized plasmid 
pETite N-His Kan vector with soluble expressed proteins purified from E. coli as described 
[19].
2.3. Immunization of mice with recombinant proteins and assessment of titer
CD-1 mice were immunized subcutaneously with approximately 15–35 μg (for single 
antigen) or approximately 2–20 ug each (for multi-antigen) recombinant protein solubilized 
in Imject (1:1) (Thermo Scientific) followed by two booster injections 3 weeks apart. Mice 
were bled 14 days following the final boost, and ELISA was performed on serum samples 
against recombinant protein to assess antibody titer as described [19].
2.4. Tick challenge of immunized mice
Immunized mice were challenged by infected nymphal stage ticks at 16–21 days following 
the last boost. Mice were anesthetized by intraperitoneal injection with a ketamine (50–100 
mg/kg) and xylazine (5–10 mg/kg) mixture prior to placement of ticks (n = 5–8/mouse).
Mice were assayed for infection at 14 days post-challenge by serology (immunoblotting 
against whole cell B. burgdorferi lysates) and culture of ear biopsies in BSK-II 
supplemented with antibiotics and fungizone as described previously [18]. Ticks collected 
from mice that were uninfected following the feed were cultured for B. burgdorferi to ensure 
that at least one infected tick had fed on the mouse. Experimental protocols involving mice 
were approved by the Institutional Animal Care and Use Committee at the Division of 
Vector Borne Diseases, CDC, Fort Collins, Colorado.
3. Results
3.1. Immunization of mice with recombinant proteins
Soluble recombinant proteins BBA64, BBA65, BBA66, BBA69, BBA70, BBA73, and OspC 
were purified for mouse immunization (Fig. 1). Groups of mice were immunized either with 
a single antigen or with a combination cocktail of antigens (Table 1). Following the second 
boost (3 injections total) and prior to infectious challenge, individual mice were bled and 
assayed for seroconversion to the specific antigen with antibody titers determined. The 
majority of mice (i.e. >90%) immunized with a particular antigen had antibody titers of 
≥25,600 indicating a robust humoral response. A representative ELISA of serum samples 
from individual mice immunized with one antigen (BBA70) is shown in Fig. 2.
3.2. B. burgdorferi infectious challenge by tick bite
Once seroconversion and antibody titers were established, mice were administered B. 
burgdorferi via tick bite transmission. Protection from challenge was assessed by serology 
and direct culturing from mouse ear tissues 2 weeks following tick feeding. Significant 
protection was not observed in mice immunized with the single antigens, BBA66 or BBA65 
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as 10/12 (p value = 0.73) and 11/11 respectively became infected (Table 1). The antigen 
combination of BBA69 and BBA70 were similarly non-protective with 11/11 mice infected 
following challenge. The four antigen combination of BBA64, BBA65, BBA66, and BBA73 
conferred protection to 3/11 mice, but this was not statistically significant compared with the 
non-immunized controls which had one mouse that did not become infected (p value = 0.63) 
(Table 1). As a control for immunization protection, 7/9 mice inoculated with OspC did not 
become infected post challenge. Ticks that fed on mice that did not become infected were 
cultured to determine whether B. burgdorferi were present. Culture results of these ticks 
indicated that at least one infected tick had fed on protected mice.
4. Discussion
Alternative antigens for a second generation Lyme disease vaccine for humans have been a 
quest for researchers since the OspA-based commercial vaccine was made unavailable by 
the manufacturer. OspC, despite studies demonstrating its protective capability, is comprised 
of multiple serotypes that may limit its protective specificity and has not been developed 
commercially for humans.
We focused on the lp54 gene products as potential vaccine candidates and have previously 
reported on the evaluation of immunization efficacy of BBA64 in mice [18]. We found that 
soluble recombinant BBA64, lipidated or non-lipidated, did not provide protective immunity 
against either needle or tick-borne challenge. Here, we tested additional lp54 gene encoded 
proteins for protective properties.
We first tested antigens BBA65 and BBA66 individually, and finding a lack of protection, 
we performed additional experiments with a combination of antigens. Our reasoning was as 
follows: (i) to simultaneously test multiple antigens in a single experiment; (ii) to determine 
whether a combination of antigens would act synergistically; and (iii) to minimize the use of 
experimental animals. Although the multi-antigen cocktail as administered contained less of 
a particular protein than the single antigen dose trials, this did not appear to be a reason for 
nonprotection as the antibody titers for each antigen were high, i.e. 1:25,600, prior to 
challenge. Our findings indicated that none of ≥the antigens provided protection in the form 
administered.
We utilized the soluble form of the recombinant antigens when purified from E. coli to 
maintain conformation that may be essential for protective epitopes. We previously found 
this to be a critical point in the formulation of protective recombinant OspC [20]. Although 
we cannot exclude the possibility that E. coli-based recombinant proteins may not have 
properly folded protective conformational epitopes, the occurrence seems unlikely. Our 
results also demonstrate that surface localization of proteins is not a sole predictor for 
protective efficacy.
In conclusion, several investigations have demonstrated that the lp54 encoded gene products 
in this study are surface exposed, expressed during tick feeding and/or in mammalian hosts, 
and elicit host antibody responses suggesting their utility as vaccine candidates. The findings 
presented here are provided to inform that the requisite experiments were performed to 
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evaluate the efficacy of these antigens as proposed alternative candidates for second 
generation Lyme disease immunogens.
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Fig. 1. 
GelCode Blue (ThermoFisher) stained SDS-PAGE of the purified recombinant proteins used 
for experimental mouse immunizations (labelled above each lane). MW = molecular weight 
markers. Numbers on the left denote molecular mass in kilodaltons.
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Fig. 2. 
Representative graph of ELISA results demonstrating antibody titers from individual mice 
prior to B. burgdorferi challenge by tick transmission. The data presented is from mice 
immunized with recombinant BBA70. Antibody titers from mice immunized with each 
antigen demonstrated similar high titers prior to challenge. M = mouse (number); M12 Con 
= control mouse mock immunized with PBS plus adjuvant only.
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